This is most probably because the NAFLD-associated alteration of XME activities will not necessarily be associated with higher levels of the toxic compounds, which can be either the parent drugs and/or CYP-generated reactive metabolites. The gene discussed is PPIG; the disease is metabolic dysfunction-associated steatotic liver disease.